Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5663834 | 0.74 | — | — | |
| SCHEMBL1802349 | 0.73 | ALDH1A1 (0.44) | — | |
| SCHEMBL5280606 | 0.71 | MGAM (0.39) | — | |
| SCHEMBL3871245 | 0.71 | TSHR (0.35) | — | |
| SCHEMBL233035 | 0.69 | LMNA (0.46) | — | |
| SCHEMBL800923 | 0.69 | — | — | |
| SCHEMBL19296381 | 0.69 | — | — | |
| SCHEMBL11727566 | 0.69 | CES1 (0.43) | — | |
| SCHEMBL6232263 | 0.69 | ALDH1A1 (0.33) | — | |
| SCHEMBL8543975 | 0.67 | ALDH1A1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1809605-B1 | QUINOLINES AS ALLOSTERIC ENHANCERS OF THE GABA-B RECEPTORS | HOFFMANN LA ROCHE (CH) | 2010-08-11 | — | — | EP | disclosed |
| US-7576217-B2 | Quinolines as allosteric enhancers of the GABAB receptors | HOFFMAN-LA ROCHE INC. (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1809605-A1 | QUINOLINE AS ALLOSTERIC ENHANCERS OF THE GABA-B RECEPTORS | F. Hoffmann-Roche AG (CH) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006048146-A1 | QUINOLINE AS ALLOSTERIC ENHANCERS OF THE GABA-B RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-11 | — | — | WO | disclosed |
| US-20060094754-A1 | Quinolines as allosteric enhancers of the GABAB receptors | HOFFMANN-LA ROCHE INC. | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094754-A1 | Quinolines as allosteric enhancers of the GABAB receptors | GABRB1, GABRB2, GABRA1 | CASP1 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.